Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.


The selective destruction of tumour cells while sparing healthy tissues is one of the main challenges in cancer therapy. Antibody-drug conjugates (ADCs) are arguably the most rapidly expanding class of targeted cancer therapies. Efficient drug conjugation and release technologies are essential for the development of these new therapeutic agents. In response… (More)
DOI: 10.1016/j.ejmech.2017.08.008


Cite this paper

@article{Kolodych2017DevelopmentAE, title={Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.}, author={Sergii Kolodych and Chlo{\'e} Michel and S{\'e}bastien Delacroix and Oleksandr Koniev and Anthony Ehkirch and Jitka Eberov{\'a} and Sarah Cianf{\'e}rani and Brigitte Renoux and Wojciech Krężel and Pauline Poinot and Christian Muller and S{\'e}bastien Papot and Alain Wagner}, journal={European journal of medicinal chemistry}, year={2017}, volume={142}, pages={376-382} }